LOGIN
ID
PW
MemberShip
2025-07-10 12:15
All News
Policy
Company
Product
Opinion
InterView
°Ë»ö
Dailypharm Live Search
Close
Company
"6-in-1 vaccine Hexaxim may enhance preventive effect of NIP
by
Whang, byung-woo
Jun 23, 2025 06:00am
"Hexaxim is Korea's first hexavalent vaccine. It is expected to play a crucial role in helping protect children's health." Following the inclusion of Hexaxim, a hexavalent (6-in-1) DTaP vaccine, in the National Immunization Program (NIP) this year, the medical field is holding high hopes for increased convenience of immunization and improveme
Company
Cream JAKi Delgocitinib to be commercialized in Korea
by
Eo, Yun-Ho
Jun 20, 2025 06:06am
JAK inhibitors will soon be available for hand eczema in Korea as well. The Ministry of Food and Drug Safety is currently conducting a final review of LEO Pharma Korea's treatment for moderate-to-severe chronic hand eczema (CHE), Anzupgo (delgocitinib). When approved, the drug is expected to be officially commercialized in the second half
Company
Interest in Lotte Biologcs¡¯ partner Ottimo Pharma rises
by
Kim, Jin-Gu
Jun 20, 2025 06:05am
Interest is growing in Ottimo Pharma, a biotech company that has signed a contract manufacturing agreement for its antibody-drug with Lotte Biologics. Founded in 2017, this UK-based biotech venture owns a new drug candidate called ¡®Jankistomig¡¯. The drug candidate bifunctional antibody targeting solid tumors, and the company plans to s
Company
New pneumococcal vaccine expected to be launched
by
Whang, byung-woo
Jun 19, 2025 06:04am
As 'Capvaxive,' a 21-valent pneumococcal conjugate vaccine (PCV21) developed by MSD, is anticipated to receive marketing authorization in South Korea, competition in the market is likely to heat up. According to pharmaceutical industry sources, MSD has filed with the Ministry of Food and Drug Safety (MFDS) for marketing authorization of Ca
Company
K-Bios face string of clinical failures in H1
by
Son, Hyung Min
Jun 19, 2025 06:04am
A series of clinical trial failures for new drug candidates under development by Korean biotech companies in the first half of the year have raised concerns about the feasibility of future technology exports. Orum Therapeutics halted a clinical trial due to safety concerns, while Genexine and Bridge Biotherapeutics both failed to demonstrate sta
Company
KOR-JPN jointly launches Healthcare Distribution Alliance
by
Son, Hyung Min
Jun 19, 2025 06:03am
Three pharmaceutical distribution companies in Korea and Japan have joined forces to launch the Healthcare Distribution Alliance to lead the domestic market by introducing advanced overseas models. The alliance aims to go beyond simple logistics agreements &8211; it seeks to build an innovative cooperation structure where companies can shar
Company
Takeda launches new drug 'Fruzaqla' in Korea
by
Whang, byung-woo
Jun 18, 2025 10:28am
Takeda Pharmaceutical Korea (CEO Kwang-kyu Park) announced on June 16 that the company has officially launched its 'Fruzaqla (fruquintinib)' in South Korea. Fruzaqla is the first new treatment for metastatic colorectal cancer. This drug selectively inhibits Vascular Endothelial Growth Factor Receptor (VEGFR)-1,2, and 3. It is expected
Company
Daiichi Sankyo exceeds ₩300B in sales¡¦new drug drives
by
Son, Hyung Min
Jun 18, 2025 06:01am
Daiichi Sankyo Korea has exceeded KRW 300 billion in sales for the first time, led by its cardiovascular products, Antibody-Drug Conjugate (ADC), and new anticancer drugs. The company is successfully transitioning its portfolio towards new ADC drugs while maintaining robust growth from established cardiovascular products like Sevikar, Lixiana, a
Company
Zejula, a new standard ovarian cancer maintenance therapy
by
Whang, byung-woo
Jun 18, 2025 06:00am
Ovarian cancer is often diagnosed at an advanced stage due to the difficulty of early detection, and it is known for its high recurrence rate even after initial treatment. First-line maintenance therapy aimed at delaying recurrence as much as possible after surgery and chemotherapy became a key strategy that determines treatment outcomes for
Company
Adstiladrin receives orphan drug designation in Korea
by
Eo, Yun-Ho
Jun 18, 2025 05:59am
The new bladder cancer drug Adstiladrin has been designated as an orphan drug in Korea. The Ministry of Food and Drug Safety recently announced the news in a orphan drug designation announcement. The specific indication for designation is ¡°treatment of BCG-refractory high-risk non-muscle-invasive bladder cancer (NMIBC) with carcinoma
1
2
3
4
5
6
7
8
9
10
>